Cannara Biotech Statistics

Total Valuation

Cannara Biotech has a market cap or net worth of CAD 116.93 million. The enterprise value is 155.64 million.

Market Cap	116.93M
Enterprise Value	155.64M

Important Dates

The last earnings date was Friday, January 24, 2025.

Earnings Date	Jan 24, 2025
Ex-Dividend Date	n/a

Share Statistics

Cannara Biotech has 90.64 million shares outstanding. The number of shares has increased by 1.10% in one year.

Current Share Class	n/a
Shares Outstanding	90.64M
Shares Change (YoY)	+1.10%
Shares Change (QoQ)	+0.06%
Owned by Insiders (%)	2.09%
Owned by Institutions (%)	n/a
Float	44.56M

Valuation Ratios

The trailing PE ratio is 17.50.

PE Ratio	17.50
Forward PE	n/a
PS Ratio	1.33
PB Ratio	1.28
P/TBV Ratio	1.29
P/FCF Ratio	11.91
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 10.61, with an EV/FCF ratio of 15.85.

EV / Earnings	23.45
EV / Sales	1.78
EV / EBITDA	10.61
EV / EBIT	18.59
EV / FCF	15.85

Financial Position

The company has a current ratio of 2.01, with a Debt / Equity ratio of 0.54.

Current Ratio	2.01
Quick Ratio	0.64
Debt / Equity	0.54
Debt / EBITDA	3.34
Debt / FCF	4.99
Interest Coverage	1.71

Financial Efficiency

Return on equity (ROE) is 7.70% and return on invested capital (ROIC) is 3.88%.

Return on Equity (ROE)	7.70%
Return on Assets (ROA)	3.42%
Return on Invested Capital (ROIC)	3.88%
Return on Capital Employed (ROCE)	6.73%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.57
Inventory Turnover	1.42

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +32.99% in the last 52 weeks. The beta is 1.21, so Cannara Biotech's price volatility has been higher than the market average.

Beta (5Y)	1.21
52-Week Price Change	+32.99%
50-Day Moving Average	0.93
200-Day Moving Average	0.74
Relative Strength Index (RSI)	73.48
Average Volume (20 Days)	47,898

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Cannara Biotech had revenue of CAD 87.28 million and earned 6.64 million in profits. Earnings per share was 0.07.

Revenue	87.28M
Gross Profit	31.67M
Operating Income	8.37M
Pretax Income	5.41M
Net Income	6.64M
EBITDA	14.39M
EBIT	8.37M
Earnings Per Share (EPS)	0.07

Full Income Statement

Balance Sheet

The company has 10.26 million in cash and 48.97 million in debt, giving a net cash position of -38.71 million or -0.43 per share.

Cash & Cash Equivalents	10.26M
Total Debt	48.97M
Net Cash	-38.71M
Net Cash Per Share	-0.43
Equity (Book Value)	90.58M
Book Value Per Share	1.01
Working Capital	36.74M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 15.73 million and capital expenditures -5.91 million, giving a free cash flow of 9.82 million.

Operating Cash Flow	15.73M
Capital Expenditures	-5.91M
Free Cash Flow	9.82M
FCF Per Share	0.11

Full Cash Flow Statement

Margins

Gross margin is 36.29%, with operating and profit margins of 9.59% and 7.60%.

Gross Margin	36.29%
Operating Margin	9.59%
Pretax Margin	6.20%
Profit Margin	7.60%
EBITDA Margin	16.49%
EBIT Margin	9.59%
FCF Margin	11.25%

Dividends & Yields

Cannara Biotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.10%
Shareholder Yield	-1.10%
Earnings Yield	5.68%
FCF Yield	8.40%

Stock Splits

The last stock split was on February 13, 2023. It was a reverse split with a ratio of 0.1.

Last Split Date	Feb 13, 2023
Split Type	Reverse
Split Ratio	0.1

Scores

Cannara Biotech has an Altman Z-Score of 1.49. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.49
Piotroski F-Score	n/a